Pharmacist Moms Group^™

Gianni Scappaticci, PharmD, BCOP, discusses key considerations in therapy selection, limitations of current treatments, and the evolving role of pharmacists in managing chronic graft-versus-host disease (cGVHD) through patient education, adherence support, and integration of emerging therapies.

An expert discusses how pharmacists can identify high-risk patients for pneumococcal disease by reviewing medication profiles for immunosuppressants and using electronic medical record vaccine tracking tools, while emphasizing that vulnerable populations face higher morbidity, mortality, and hospitalization rates compared with healthy individuals.

Panelists discuss how the use of both clinician- and patient-reported scales—such as the Impact TD scale, TDIS, and Impact TD Pro—enhances understanding of tardive dyskinesia’s true impact on daily functioning and quality of life, emphasizing the importance of incorporating patient perspectives to guide early, personalized treatment strategies that improve physical symptoms and overall well-being.

Panelists discuss how tardive dyskinesia in older adults often goes unrecognized due to symptom overlap with normal aging, underscoring the importance of early screening, timely intervention with evidence-based treatments like VMAT2 inhibitors, and a multidisciplinary approach to preserve function, independence, and mental well-being.

An expert discusses how pneumococcal disease presents differently across age groups, with children primarily experiencing ear infections, whereas adults face more serious, invasive complications such as bacteremia and meningitis, though vaccination efforts have significantly reduced overall incidence rates.

An expert discusses how different tyrosine kinase inhibitor (TKI) mechanisms of action, including asciminib’s allosteric binding vs traditional ATP-competitive inhibitors, influence treatment selection based on off-target effects and adverse effect profiles, with patients with advanced-phase chronic myeloid leukemia (CML) requiring second-generation or higher TKIs for faster response rates.

An expert discusses how National Comprehensive Cancer Network (NCCN) guidelines recommend first-line chronic myeloid leukemia (CML) treatments including imatinib, nilotinib, and newer agents, emphasizing the importance of close monitoring through weekly laboratory tests and quantitative polymerase chain reaction (PCR) to track BCR::ABL1 transcript levels and ensure patients meet critical milestones at 3, 6, and 12 months.

Shaji Kumar, MD, shares data and insights from the phase 2 RedirecTT-1 study.

Megan Ehret, PharmD, MS, BCPP, FAAPP, discusses the clinical benefits of long-acting injectables for treating alcohol use disorder and psychiatric conditions, highlighting the pharmacist’s role in improving adherence, addressing stigma, and expanding access to care.